Furosemide is a loop diuretic indicated for edema associated with heart failure, cirrhosis and renal disease, and hypertension. We supply it to US manufacturers of tablets, oral solution and injection.
Data from PubChem (CID 3440) and FDA’s substance registry
CAS number
54-31-9
Molecular formula
C12H11ClN2O5S
Molecular weight
330.7g/mol
FDA UNII
IUPAC name
4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid
InChIKey
ZZUFCTLCJUWOSV-UHFFFAOYSA-N
- Appearance
- White to slightly yellowish, odorless crystalline powder.
- Solubility
- Practically insoluble in water, sparingly soluble in alcohol, freely soluble in dilute alkali solutions and insoluble in dilute acids.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
Discolors on exposure to light, so light-resistant packaging matters. Injection-grade material carries tighter limits than oral grade; say which you need.
On the US market
- Reference product
- LasixNDA 016273
- Approved ANDAs
- 22 with a marketed product
- Approved forms and strengths
- Tablet 20 mg, 40 mg, 80 mg
- Injection 10 mg/mL
- Subcutaneous injection 80 mg/10 mL, 80 mg/2.67 mL, 80 mg/mL
- Oral solution 10 mg/mL, 40 mg/5 mL
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com